baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. PUT 12/24 QIA/ DE000HD3CXT9 /

2024-09-03 9:40:09 PM	Chg.+0.0400	Bid9:59:06 PM	Ask9:59:06 PM	Underlying	Strike price	Expiration date	Option type
0.2600EUR	+18.18%	0.2500 Bid Size: 15,000	0.2800 Ask Size: 15,000	QIAGEN NV	40.00 -	2024-12-18	Put

GlobeNewswire 08-28 QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in c...

TeleTrader 08-26 Europe closes mixed amid Middle East crisis

GlobeNewswire 07-31 QIAGEN delivers solid performance and exceeds outlook for Q2 2024

GlobeNewswire 07-31 Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

GlobeNewswire 07-08 QIAGEN to enhance the identification of human remains of Indigenous people and African Americans

GlobeNewswire 07-02 QIAGEN N.V. to release results for Q2 2024 and hold webcast

GlobeNewswire 06-27 QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis in...

GlobeNewswire 06-17 QIAGEN announces 2028 strategy for solid profitable growth

GlobeNewswire 06-13 QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput N...

GlobeNewswire 06-12 QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to su...

GlobeNewswire 06-11 QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious dis...

GlobeNewswire 06-06 QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition per...

GlobeNewswire 06-05 QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of it...

GlobeNewswire 06-03 QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improv...

GlobeNewswire 05-30 QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...

GlobeNewswire 05-29 QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision ...

GlobeNewswire 05-22 deepull appoints Didier Deltort to its Board of Directors

GlobeNewswire 05-14 QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...

GlobeNewswire 05-13 QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...

GlobeNewswire 05-07 QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

GlobeNewswire 05-07 Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq

GlobeNewswire 05-02 QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...

GlobeNewswire 04-29 QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance

UC WAR. PUT 12/24 QIA/ DE000HD3CXT9 /

If you wish to receive reply to your feedback, please provide your email address.